PARLIAMENTARY WRITTEN QUESTION
Cancer Drugs Fund (10 November 2015)

To ask the Secretary of State for Health, pursuant to the Answer of 16 September 2015 to Question 10091, what the implications for his policies are of the decision by NHS England to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund List.

Asked by:
Sir Nicholas Dakin (Labour)

We remain committed to continuing to invest in the Cancer Drugs Fund (CDF).

NHS England is responsible for the operational management of the Fund. Following appeals and further discussions with pharmaceutical companies, 18 drug and indication combinations, including Abraxane for pancreatic cancer, were removed from the national CDF list on 4 November 2015.

Answered by:
George Freeman (Conservative)
17 November 2015